Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of inhaled glycopyrronium bromide in moderate to severe COPD
2012-003791-40Phase 2Completed
- Sponsor
- Prosonix
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Prosonix. Started Oct 2012; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2012-003791-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003791-40.